The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

(HealthDay News) — The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

▎药明康德内容团队编辑GSK日前宣布，美国FDA已批准其组合疫苗Penmenvy（MenABCWY）上市，在10~25岁人群中使用。这款疫苗针对脑膜炎球菌中最常见的5大血清群，它们通常是导致侵袭性脑膜炎球菌病（IMD）的原因。此前，该疗法入选了业内知 ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

GSK has secured approval from the US Food and Drug Administration (FDA) for its new vaccine, Penmenvy, to protect against five meningococcal serogroups for individuals aged ten to 25. The vaccine ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake ...